Editorial

The Role of Exosomes in Health and Disease

Vincenzo Lionetti

1 Unit of Translational Critical Care Medicine, Scuola Superiore Sant’Anna, 56127 Pisa, Italy; v.lionetti@santannapisa.it
2 UOSVD Anesthesiology and Intensive Care Medicine, Fondazione Toscana “Gabriele Monasterio”, 56124 Pisa, Italy

Who would have thought that the discovery made by researchers at Washington University [1] and McGill University [2] almost 40 years ago would help us to fully understand the adaptive and maladaptive responses of a tissue to a change in the extracellular microenvironment? At the time, it was surprising to observe how maturing blood reticulocytes secreted transferrin receptors within hitherto unexpected tiny membranous vesicles, later named exosomes by Dr. Rose M Johnstone. Today, we know that nanovesicles release is an extraordinary mode of communication of all cells in health and disease throughout life [3–5], even in dying cells [6]. However, not all extracellular vesicles (EVs) are the same. There is growing evidence that exosomes (size 30–150 nm), once they are released externally from endosomes, carry varieties of signals produced by the sorting of different proteins, oligonucleotides (e.g., mRNA, microRNA, circRNA, mtDNA), or metabolites (e.g., lipids, amino acids), even in plants.

Of note, Woith et al. [7] have demonstrated that lipophilic compounds are associated with nanovesicles, while more hydrophilic structures are not consistently found. We can consider this finding of particular interest since plant cells secrete EVs using similar mechanisms as mammal cells. Moreover, plant-derived exosome content could contribute to the potential protective effects of functional foods that enrich our diet as major regulators of the human epigenome [8].

Despite the large number of studies published so far, further investigation of the mechanisms underlying exosomal regulation of organ function is needed to better highlight its clinical relevance, even in critically ill patients [9]. Indeed, we cannot exclude that the efficiency of this type of intercellular communication even depends on the susceptibility of recipient cells toward selective exosomes under specific microenvironment. For example, some conventional drugs may increase the release of antiapoptotic exosomes targeting cardiomyocytes [10]. Moreover, EV trafficking is involved in inter-tissue communication during exercise, delivering a wide range of adhesion proteins [11]. Beyond this initial evidence, it is still unclear how an external chemical and/or physical stimulus changes the content of an exosome or interferes with its release and internalization under physiological and pathological conditions. We cannot ignore, however, that changes in the circulating levels of exosomes can play a theranostic and prognostic key role in patients with cardiovascular diseases, even in those undergoing cardiac surgery [12–14]; acute lung injury/acute respiratory distress syndrome [15]; neurodegenerative disorders [16]; COVID-19 [17]; and other severe diseases, as summarized in this Special Issue. Levin et al. [18] demonstrated that circulating EVs in patients with beta thalassemia major contain high levels of miR-144-3p, a regulator of erythropoiesis, which leads to the proliferation of bone marrow mesenchymal stem cells and reduced survival of endothelial, pancreatic, and hepatic cells, contributing to the onset of organ dysfunction. As a result, there is an increasing need to draft international guidelines to enable exosome-based liquid biopsy in clinical practice and to develop new assays to better quantify and characterize exosomes in both preclinical laboratories and in hospital settings [19]. In light of this topic, Mason et al. [20] have described a unique chip-based approach for the real-time monitoring of nanovesicles...
crosstalk between different cell populations that are physically separated by an extracellular matrix-mimicking Matrigel under physiologically relevant conditions. Therefore, the use of a multimodal platform to study exosome-mediated intercellular communication has also revealed their potential dose-dependent therapeutic value, which is dependent on the cell source, timing, and mode of administration. For the first time, Barile et al. [21] have shown the dose-dependent inhibition of cardiomyocyte apoptosis by extracellular vesicles derived from cardiac progenitor cells, but not fibroblast-derived exosomes. Thanks to the most recent translational studies, exosomes are considered a new horizon in the cell-free therapy of otherwise incurable diseases, although clinical data on the kinetics and dynamics of a single dose of exosomes are lacking. Finally, exosomes have been proposed as drug transporters for precision medicine, although their use for this purpose has been limited by the lack of efficient drug-loading methods. In this regard, Romano et al. [22] have demonstrated that the manipulation of vesicles curvature by high-pressure homogenization successfully improves and shortens the exosome encapsulation process of the bioactive agent to less than 1 h, preserving their morphological integrity and biological identity. This technology could also be effective in facilitating the development of a new multi-modal molecular imaging approach to guide therapy and surgery by encapsulating the contrast agents or nanoparticles and exploiting the inherent echogenicity of exosomes at the same time [23].

More extensive multidisciplinary studies are needed to fill in the gaps and to overcome the limitations of available technologies in order to reposition exosomes in the first line for their use in the nanobiotheranostic field.

The purpose of this research topic was to bring together state-of-the-art original research and review articles on the latest evidence in the field of exosome-based applications. It is hoped that in the future, readers of this Special Issue will be inspired to develop more effective and less invasive precision approaches to promote the wide use of exosomes at bedside.

Funding: This research received no external funding.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Harding, C.; Stahl, P. Transferrin recycling in reticulocytes: pH and iron are important determinants of ligand binding and processing. Biochem. Biophys. Res. Commun. 1983, 113, 650–658. [CrossRef]
2. Pan, B.T.; Johnstone, R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. Cell 1983, 33, 967–978. [CrossRef]
3. Liu, D.S.K.; Yang, Q.Z.C.; Asim, M.; Krell, J.; Frampton, A.E. The Clinical Significance of Transfer RNAs Present in Extracellular Vesicles. Int. J. Mol. Sci. 2022, 23, 3692. [CrossRef] [PubMed]
4. Chang, L.C.; Chiu, H.M.; Wu, M.S.; Shen, T.L. The Role of Small Extracellular Vesicles in the Progression of Colorectal Cancer and Its Clinical Applications. Int. J. Mol. Sci. 2022, 23, 1379. [CrossRef] [PubMed]
5. Costa, A.; Quarto, R.; Bollini, S. Small Extracellular Vesicles from Human Amniotic Fluid Samples as Promising Theranostics. Int. J. Mol. Sci. 2022, 23, 590. [CrossRef] [PubMed]
6. Kakarla, R.; Hur, J.; Kim, Y.J.; Kim, J.; Chwae, Y.J. Apoptotic cell-derived exosomes: Messages from dying cells. Exp. Mol. Med. 2020, 52, 1–6. [CrossRef]
7. Woith, E.; Guerriero, G.; Hausman, J.F.; Renault, J.; Leclercq, C.C.; Weise, C.; Legay, S.; Weng, A.; Melzig, M.F. Plant Extracellular Vesicles and Nanovesicles: Focus on Secondary Metabolites, Proteins and Lipids with Perspectives on Their Potential and Sources. Int. J. Mol. Sci. 2021, 22, 3719. [CrossRef]
8. Lionetti, V.; Tuana, B.S.; Casieri, V.; Parikh, M.; Pierce, G.N. Importance of functional food compounds in cardioprotection through action on the epigenome. Eur. Heart J. 2019, 40, 575–582. [CrossRef] [PubMed]
9. Terrasini, N.; Lionetti, V. Exosomes in Critical Illness. Crit. Care Med. 2017, 45, 1054–1060. [CrossRef]
10. Casieri, V.; Matteucci, M.; Pasanisi, E.M.; Papa, A.; Barile, L.; Fritzsche-Danielson, R.; Lionetti, V. Ticagrelor Enhances Release of Anti-Hypoxic Cardiac Progenitor Cell-Derived Exosomes through Increasing Cell Proliferation In Vitro. Sci. Rep. 2020, 10, 2494. [CrossRef] [PubMed]
11. Whitham, M.; Parker, B.L.; Friedrichsen, M.; Hingst, J.R.; Hjorth, M.; Hughes, W.E.; Egan, C.L.; Cron, L.; Watt, K.J.; Kuchel, R.P.; et al. Extracellular Vesicles Provide a Means for Tissue Crosstalk during Exercise. Cell Metab. 2018, 27, 237–251. [CrossRef] [PubMed]
12. Pizzino, F.; Furini, G.; Casieri, V.; Mariani, M.; Bianchi, G.; Storti, S.; Chiappino, D.; Maffei, S.; Solinas, M.; Aquaro, G.D.; et al. Late plasma exosome microRNA-21-5p depicts magnitude of reverse ventricular remodeling after early surgical repair of primary mitral valve regurgitation. *Front. Cardiovasc. Med.* **2022**, *9*, 943068. [CrossRef] [PubMed]

13. Carrozzo, A.; Casieri, V.; Di Silvestre, D.; Brambilla, F.; De Nitto, E.; Sardaro, N.; Papini, G.; Storti, S.; Settanni, G.; Solinas, M.; et al. Plasma exosomes characterization reveals a perioperative protein signature in older patients undergoing different types of on-pump cardiac surgery. *Geroscience* **2021**, *43*, 773–789. [CrossRef] [PubMed]

14. Zarà, M.; Campodonico, J.; Cosentino, N.; Biondi, M.L.; Amadio, P.; Milanesi, G.; Assanelli, E.; Cerri, S.; Biggiogera, M.; Sandrini, L.; et al. Plasma Exosome Profile in ST-Elevation Myocardial Infarction Patients with and without Out-of-Hospital Cardiac Arrest. *Int. J. Mol. Sci.* **2021**, *22*, 8065. [CrossRef]

15. Liu, C.; Xiao, K.; Xie, L. Progress in preclinical studies of macrophage autophagy in the regulation of ALI/ARDS. *Front. Immunol.* **2022**, *13*, 922702. [CrossRef] [PubMed]

16. Athauda, D.; Gulyani, S.; Karnati, H.K.; Li, Y.; Tweedie, D.; Mustapic, M.; Chawla, S.; Chowdhury, K.; Skene, S.S.; Greig, N.H.; et al. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients with Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. *JAMA Neurol.* **2019**, *76*, 420–429. [CrossRef]

17. Burrello, J.; Caporali, E.; Gauthier, L.G.; Pianezzi, E.; Balbi, C.; Rigamonti, E.; Bolis, S.; Lazzarini, E.; Biemmi, V.; Burrello, A.; et al. Risk stratification of patients with SARS-CoV-2 by tissue factor expression in circulating extracellular vesicles. *Vasc. Pharmacol.* **2022**, *145*, 106999. [CrossRef]

18. Levin, C.; Koren, A.; Rebibo-Sabbah, A.; Levin, M.; Koifman, N.; Brenner, B.; Aharon, A. Extracellular Vesicle MicroRNA That Are Involved in β-Thalassemia Complications. *Int. J. Mol. Sci.* **2021**, *22*, 9760. [CrossRef]

19. Lener, T.; Gimona, M.; Aigner, L.; Börger, V.; Buzas, E.; Camussi, G.; Chaput, N.; Chatterjee, D.; Court, F.A.; Del Portillo, H.A.; et al. Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper. *J. Extracell. Vesicles* **2015**, *4*, 30087. [CrossRef]

20. Mason, H.G.; Bush, J.; Agrawal, N.; Hakami, R.M.; Veneziano, R. A Microfluidic Platform to Monitor Real-Time Effects of Extracellular Vesicle Exchange between Co-Cultured Cells across Selectively Permeable Barriers. *Int. J. Mol. Sci.* **2022**, *23*, 3534. [CrossRef]

21. Barile, L.; Lionetti, V.; Cervio, E.; Matteucci, M.; Gherghiceanu, M.; Popescu, L.M.; Torre, T.; Siclari, E.; Mocetti, T.; Vassalli, G. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. *Cardiovasc. Res.* **2014**, *103*, 530–541. [CrossRef] [PubMed]

22. Romano, E.; Netti, P.A.; Torino, E. A High Throughput Approach Based on Dynamic High Pressure for the Encapsulation of Active Compounds in Exosomes for Precision Medicine. *Int. J. Mol. Sci.* **2021**, *22*, 9896. [CrossRef] [PubMed]

23. Osborn, J.; Pullan, J.E.; Froberg, J.; Shreffler, J.; Gange, K.N.; Molden, T.; Choi, Y.; Brooks, A.; Mallik, S.; Sarkar, K. Echogenic Exosomes as ultrasound contrast agents. *Nanoscale Adv.* **2020**, *2*, 3411–3422. [CrossRef] [PubMed]